학술논문
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
Document Type
Article
Author
Source
In: Journal of Allergy and Clinical Immunology . (Journal of Allergy and Clinical Immunology, February 2024, 153(2):479-486.e4)
Subject
Language
English
ISSN
10976825
00916749
00916749